The transgenic line, designated R962-hTau, developed numerous primary and secondary features associated with AD and other tauopathies, including filamentous tau inclusions, cognitive deficits, brain atrophy, ventricular dilation, neuronal loss, myelin degeneration and a progressive glial response. This evidence concerns the gene MAPT and tauopathy.